Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 191-199

  Kekow, Joern ^a   Mueller Ladner, Ulf ^b   Schulze Koops, Hendrik ^c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti cyclic citrullinated peptide antibodies; Rheumatoid arthritis; Rheumatoid factor; Rituximab

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; INFLIXIMAB; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; EYE SWELLING; FATIGUE; FEMALE; HUMAN; HYPESTHESIA; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NAIL DYSTROPHY; PRURITUS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 84866773063     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s32244     Document Type: Article

References (26)

1. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S32-S40.
2. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010;69(11):1898-1906.
3. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S52-S57.
4. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum. 2003;48(12):3308-3319.
5. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806.
6. Keystone E, Burmester GR, Furie R, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59(6):785-793.
7. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(2):353-363.
8. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594-1602.
9. Seymour HE, Worsley A, Smith JM, Thomas SH. Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol. 2001;51(3):201-208.
10. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA Trial. Arthritis Rheum. 2003;48(1):35-45.
11. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-259.
12. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
13. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40(2):205-211.
14. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-1400.
15. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56(5):1417-1423.
16. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69(2):387-393.
17. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van der Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.
18. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93-S99.
19. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-145.
20. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68(2):216-221.
21. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69-74.
22. Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev. 2010;9(12):801-803.
23. Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009;48(12):1557-1559.
24. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70(1):39-46.
25. Strangfeld A, Eveslage M, Kekow J, et al. Effectiveness of treatment with rituximab depends on autoantibody status: results from 2 years of experience in the German biologics register RABBIT [Abstract]. Arthritis Rheum. 2009;60 Suppl 10:1695.
26. Isaacs JD, Ferracioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis. 2011;70(1):4-7.